SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 398 filers reported holding SEATTLE GENETICS INC in Q4 2019. The put-call ratio across all filers is 0.69 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,162,000 | +3.4% | 5,936 | -10.3% | 0.04% | +8.8% |
| Q2 2020 | $1,124,000 | +23.9% | 6,614 | -15.9% | 0.03% | +36.0% |
| Q1 2020 | $907,000 | +24.1% | 7,864 | +22.9% | 0.02% | +92.3% |
| Q4 2019 | $731,000 | -7.0% | 6,401 | -30.4% | 0.01% | -7.1% |
| Q3 2019 | $786,000 | -5.3% | 9,201 | -23.3% | 0.01% | +7.7% |
| Q2 2019 | $830,000 | -22.0% | 11,990 | -17.4% | 0.01% | -18.8% |
| Q1 2019 | $1,064,000 | +171.4% | 14,521 | +110.0% | 0.02% | +166.7% |
| Q4 2018 | $392,000 | -75.8% | 6,916 | -77.9% | 0.01% | -73.9% |
| Q2 2017 | $1,618,000 | -70.4% | 31,269 | -64.0% | 0.02% | -66.7% |
| Q1 2017 | $5,459,000 | +701.6% | 86,842 | +573.2% | 0.07% | +666.7% |
| Q4 2016 | $681,000 | +53.0% | 12,900 | +56.5% | 0.01% | +50.0% |
| Q3 2016 | $445,000 | -63.4% | 8,242 | -72.6% | 0.01% | -60.0% |
| Q2 2016 | $1,216,000 | – | 30,082 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 51,049,760 | $3,738,884,000 | 23.93% |
| Lagoda Investment Management, L.P. | 76,873 | $5,630,000 | 7.16% |
| Matrix Capital Management Company, LP | 3,141,852 | $230,109,000 | 6.14% |
| DOMINI IMPACT INVESTMENTS LLC | 3,120 | $229,000 | 3.51% |
| Opus Point Partners Management, LLC | 17,832 | $1,306,000 | 1.77% |
| Capital International Sarl | 188,200 | $13,784,000 | 1.72% |
| EMORY UNIVERSITY | 33,368 | $2,444,000 | 1.72% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,900 | $4,460,000 | 1.65% |
| CAPITAL GUARDIAN TRUST CO | 1,358,254 | $99,415,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 150,598 | $11,030,000 | 1.29% |